Related Experiment Video
Updated: Jul 7, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer
T M Murphy1, A S Perry, M Lawler
1Prostate Cancer Research Group, Institute of Molecular Medicine, Trinity College Dublin, Ireland. murphyth@tcd.ie
Abstract:
It is now well established that cancer cells exhibit a number of genetic defects in the machinery that governs programmed cell death and that sabotage of apoptosis is one of the principal factors aiding in the evolution of the carcinogenic phenotype. A number of studies have implicated aberrant DNA methylation as a key survival mechanism in cancer, whereby promoter hypermethylation silences genes essential for many processes including apoptosis. To date, studies on the methylation profile of apoptotic genes have largely focused on cancers of the breast, colon and stomach, with only limited data available on prostate cancer. Here we discuss the major developments in the field of DNA methylation and its role in the regulation of aberrant apoptosis in prostate cancer. The most significant advances have involved the discovery of apoptotic gene targets of methylation, including XAF1, (fragile histidine triad (FHIT ), cellular retinol binding protein 1 (CRBP1), decoy receptor 1(DCR1), decoy receptor 2 (DCR2 ), target of methylation-induced silenceing 1 (TMS1), TNF receptor superfamily, member 6 (FAS), Reprimo (RPRM) and GLI pathogenesis-related 1 (GLIPR1). These genes are reported to be hypermethylated in prostate cancer and some offer potential as diagnostic and prognostic markers. We also introduce the concept of an 'apoptotic methylation signature' for prostate cancer and evaluate its potential in a diagnostic, prognostic and therapeutic setting.
Insights
Aberrant DNA methylation silences genes crucial for programmed cell death (apoptosis) in cancer. This study explores DNA methylation
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Cancer cells often have genetic defects in programmed cell death (apoptosis) machinery.
- Aberrant DNA methylation, specifically promoter hypermethylation, silences essential genes, aiding cancer survival.
- Limited research exists on apoptotic gene methylation in prostate cancer compared to other cancers.
Purpose of the Study:
- To review developments in DNA methylation and its role in aberrant apoptosis in prostate cancer.
- To identify key apoptotic gene targets affected by methylation in prostate cancer.
- To evaluate the potential of an 'apoptotic methylation signature' for prostate cancer diagnosis, prognosis, and therapy.
Main Methods:
- Literature review focusing on DNA methylation and apoptosis in prostate cancer.
- Identification and discussion of specific hypermethylated apoptotic genes in prostate cancer.
- Conceptualization and evaluation of an 'apoptotic methylation signature'.
Main Results:
- Several apoptotic genes, including XAF1, FHIT, CRBP1, DCR1, DCR2, TMS1, FAS, RPRM, and GLIPR1, are frequently hypermethylated in prostate cancer.
- These hypermethylated genes represent key targets in the dysregulation of apoptosis.
- Some of these genes show potential as diagnostic and prognostic markers for prostate cancer.
Conclusions:
- DNA methylation plays a significant role in the aberrant apoptosis observed in prostate cancer.
- The identified apoptotic genes are critical targets for understanding prostate cancer development.
- An 'apoptotic methylation signature' holds promise for clinical applications in prostate cancer management.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle

